GlassScriptPhysician profile
Sarah Knowlton
NPI 1558716852
$882.67
in general payments reported to CMS, 2019-2025
16 companies · $67.90 in 2025
The $67.90 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.36 · 2023: $370 · 2024: $372 · 2025: $67.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.43 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.57 | 2023-2024 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $93.40 | 2023-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $92.27 | 2023-2024 | Entyvio, Eohilia |
| Astrazeneca Pharmaceuticals LP | $73.36 | 2022 | |
| Lilly USA, LLC | $68.95 | 2023-2024 | Omvoh |
| Sumitomo Pharma America, INC. | $48.93 | 2025 | Myfembree |
| Celgene Corporation | $47.55 | 2023 | Zeposia |
| Fresenius Kabi USA, LLC | $31.76 | 2023-2024 | Idacio |
| Genzyme Corporation | $25.45 | 2024 | |
| Amgen INC. | $24.60 | 2023 | Amjevita, Avsola |
| Qol Medical, LLC | $21.73 | 2024 | Sucraid |
| Janssen Biotech, INC. | $19.59 | 2023 | Simponi, Remicade, Stelara |
| Aimmune Therapeutics, INC. | $17.08 | 2024 | |
| Merck Sharp & Dohme LLC | $16.73 | 2023 | Zinplava, Dificid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $14.27 | 2023 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Knowlton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.